CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
+9.76%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.21
- Revenue estimate
- $16.0M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.19
- EPS estimate
- -$0.25
- Revenue actual
- $14.3M
- Revenue estimate
- $14.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.5%
- Revenue beats (12Q)
- 1
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.25 | -$0.19 | Beat 24.00% | $14.3M |
| May 11, 2026 | -$0.26 | -$0.25 | Beat 5.06% | $12.3M |
| Mar 9, 2026 | -$0.36 | -$0.34 | Beat 4.25% | $12.7M |
| Nov 6, 2025 | -$0.32 | -$0.33 | Miss -3.13% | $11.6M |
| Aug 7, 2025 | -$0.31 | -$0.34 | Miss -9.68% | $10.3M |
| Mar 10, 2025 | -$0.10 | -$0.28 | Miss -180.00% | $54.1M |
| Aug 8, 2024 | -$0.21 | -$0.14 | Beat 33.33% | $65.0M |
| May 9, 2024 | -$0.05 | -$0.32 | Miss -540.00% | $77.1M |
| Mar 13, 2024 | -$0.21 | -$0.62 | Miss -195.24% | $91.5M |
| Aug 2, 2023 | -$0.52 | -$0.38 | Beat 26.92% | $58.7M |
| Mar 6, 2023 | -$0.64 | -$0.60 | Beat 6.25% | $45.4M |
| Aug 4, 2022 | -$0.96 | -$0.65 | Beat 32.29% | $60.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026